This instrument is the National Health (Immunisation Program — Designated Vaccines) Amendment Determination 2025.

This instrument commences the day after this instrument is registered.

This instrument is made under subsection 9B(2) of the National Health Act 1953.

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Immunisation Program — Designated Vaccines) Determination 2014 (No.1)

1 After subsection 7(1)

Insert:

(1C) For item 111B of Schedule 1, the circumstances are that a designated vaccine referred to in that item may be provided to:

(a) a child who is about 6 months old and is an Aboriginal person or Torres Strait Islander; or

(b) a child who is about 6 months old and has one or more of the following medical risk conditions:

(i) functional or anatomical asplenia, including sickle cell disease, other haemoglobinopathies, congenital or acquired asplenia (e.g. splenectomy) or hyposplenia; or

(ii) immunocompromising conditions, including congenital or acquired immune deficiency including symptomatic IgG subclass or isolated IgA deficiency, haematological malignancies, solid organ transplant, haematopoietic stem cell transplant or HIV infection; or

(iv) chronic respiratory disease, including suppurative lung disease, bronchiectasis and cystic fibrosis or chronic lung disease of prematurity; or

(v) chronic renal disease, including end stage renal disease (eGFR <15mL/min) or relapsing or persistent nephrotic syndrome; or

(vi) proven or presumptive cerebrospinal fluid leak; or

(vii) cochlear implants; or

(viii) intracranial shunts; or

(ix) previous episode of invasive pneumococcal disease; or

(x) born less than 28 weeks gestation; or

(xi) trisomy 21; or

(xii) chronic heart disease including cyanotic heart disease and heart failure; or

(c) a child who is at least 12 months old but less than 5 years old and has been newly diagnosed with one or more of the medical risk conditions referred to in paragraph (b); or

(d) a child who is at least 5 years old but less than 18 years old and has been newly diagnosed with one or more of the medical risk conditions referred to in subparagraphs (b)(i) to (ix).

2 After item 111 of the table in Part 1 of Schedule 1

Insert:

111A

Vaccine

Pneumococcal (conjugate, 20‑valent)

Circumstances

Vaccine may be provided to a child who is:

about 2 months old;
about 4 months old; or
about 12 months old but less than 24 months old

Prevenar 20

Injection (0.5mL)

Polysaccharides of the capsular antigens of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F individually conjugated to Corynebacterium diphtheriae CRM197 protein

Maximum of 3 doses:

(a) one dose given at about 2 months old;

(b) one dose given at about 4 months old;

111B

Vaccine

Pneumococcal (conjugate, 20‑valent)

Circumstances

Vaccine may be provided in one of the circumstances set out in subsection 7(1C).

If a person has already received a dose under this item, they are not eligible to receive another dose under this item

Prevenar 20

Injection (0.5mL)

Maximum of 1 dose